MDM2 and cancer: In sum, the results suggest therapy-resistant tetraploid cells, by virtue of having higher P53 gene copy number and expressing twice as many p53-MDM2 complexes, are more sensitive than diploid cells to anti-cancer MDM2 antagonists (e.g. Nutlin).